⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VYGR News
Voyager Therapeutics, Inc. Common Stock
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Voyager Reports First Quarter 2026 Financial and Operating Results
globenewswire.com
VYGR
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Form 8-K
sec.gov
VYGR
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
globenewswire.com
VYGR
Voyager to Present at Upcoming Investor Conferences
globenewswire.com
VYGR
Voyager Reports Third Quarter 2025 Financial and Operating Results
globenewswire.com
VYGR
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
globenewswire.com
VYGR